恩替卡韦预防23个月后嵌合抗原受体T细胞疗法后的乙型肝炎病毒再激活
Post-Chimeric Antigen Receptor T-Cell Therapy Hepatitis B Virus Reactivation After 23 Months of Entecavir Prophylaxis.
作者信息
McKinney Caleb J C, Bigelow William, Venkat Preethi G, Shah Neeral L
机构信息
Department of Internal Medicine, University of Virginia, Charlottesville, VA.
Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA.
出版信息
ACG Case Rep J. 2024 Sep 12;11(9):e01515. doi: 10.14309/crj.0000000000001515. eCollection 2024 Sep.
Hepatitis B virus (HBV) reactivation can occur in immunosuppressed patients. Specifically, HBV reactivation after chimeric antigen receptor T-cell (CAR T-cell) therapy is a known complication with few case reports and specific treatment guidelines. Our patient experienced HBV reactivation 27 months after CAR T-cell therapy even with 23 months of entecavir prophylaxis. This unique case highlights the need for further investigation into the risk of HBV reactivation after CAR T-cell therapy and the proper HBV prophylaxis during and after CAR T-cell therapy.
乙型肝炎病毒（HBV）再激活可发生在免疫抑制患者中。具体而言，嵌合抗原受体T细胞（CAR-T细胞）治疗后的HBV再激活是一种已知的并发症，病例报告较少且缺乏具体的治疗指南。即使接受了23个月的恩替卡韦预防治疗，我们的患者在CAR-T细胞治疗27个月后仍发生了HBV再激活。这一独特病例凸显了进一步研究CAR-T细胞治疗后HBV再激活风险以及CAR-T细胞治疗期间和之后适当进行HBV预防的必要性。
Zotero 插件